^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jatenzo (testosterone undecanoate)

    i
    Other names: CLR-610
    Associations

    News

    Trials
    Company:
    Tolmar
    Drug class:
    Testosterone agonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=15, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Completed | N=30 --> 15 | Trial completion date: Dec 2027 --> Aug 2025 | Trial primary completion date: Dec 2025 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jatenzo (testosterone undecanoate)
    10ms
    Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • Jatenzo (testosterone undecanoate)
    11ms
    Testosterone Treatment in Men with Chronic Kidney Disease (clinicaltrials.gov)
    P2, N=20, Recruiting, St. Louis University | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Jatenzo (testosterone undecanoate)
    over1year
    A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months (clinicaltrials.gov)
    P4, N=110, Active, not recruiting, Tolmar Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jatenzo (testosterone undecanoate)
    almost2years
    A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months (clinicaltrials.gov)
    P4, N=110, Recruiting, Tolmar Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jatenzo (testosterone undecanoate)
    almost2years
    A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months (clinicaltrials.gov)
    P4, N=110, Not yet recruiting, Tolmar Inc.
    New P4 trial
    |
    Jatenzo (testosterone undecanoate)
    almost2years
    Testosterone Treatment in Men With Chronic Kidney Disease (clinicaltrials.gov)
    P2, N=20, Recruiting, St. Louis University | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Jatenzo (testosterone undecanoate)
    2years
    Patient Satisfaction After Switching to Oral Testosterone Undecanoate (clinicaltrials.gov)
    P4, N=41, Completed, University of Miami | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> Apr 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    Jatenzo (testosterone undecanoate)
    almost4years
    Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    Xtandi (enzalutamide) • Jatenzo (testosterone undecanoate)